Comparative Pharmacology
Head-to-head clinical analysis: CHILDREN S MOTRIN versus NAPROXEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHILDREN S MOTRIN versus NAPROXEN.
CHILDREN'S MOTRIN vs NAPROXEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, thereby decreasing pain, fever, and inflammation.
Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), thereby reducing the synthesis of prostaglandins involved in inflammation, pain, and fever.
200-400 mg orally every 6-8 hours as needed; maximum 1200 mg/day without prescription, extended release forms: 600-800 mg orally twice daily.
250-500 mg orally twice daily; maximum 1.5 g/day. For extended-release: 750-1000 mg orally once daily.
None Documented
None Documented
Clinical Note
moderateNaproxen + Gatifloxacin
"Naproxen may increase the neuroexcitatory activities of Gatifloxacin."
Clinical Note
moderateNaproxen + Rosoxacin
"Naproxen may increase the neuroexcitatory activities of Rosoxacin."
Clinical Note
moderateNaproxen + Levofloxacin
"Naproxen may increase the neuroexcitatory activities of Levofloxacin."
Clinical Note
moderateNaproxen + Trovafloxacin
"Naproxen may increase the neuroexcitatory activities of Trovafloxacin."
2-4 hours in children; prolonged in neonates and hepatic impairment.
Terminal elimination half-life 12-17 hours (mean 14 hours); permits twice-daily dosing. Half-life prolonged in elderly and hepatic impairment.
Renal (90%) as inactive metabolites and conjugates; fecal (<5%).
Primarily renal (95% as unchanged naproxen and 6-O-desmethylnaproxen); <5% fecal via biliary excretion.
Category C
Category D/X
NSAID
NSAID